Funan Liu

Key Laboratory Of Precision Diagnosis And Treatment Of Gastrointestinal Tumors
Shenyang, 110001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Nanomedicine for targeting crosstalk between nerves and cancer.

Nanomedicine for targeting crosstalk between nerves and cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 10, 2026

Oncolytic virus-drug conjugates for increased viral replication efficiency and potentiated cancer chemoimmunotherapy.

Oncolytic virus-drug conjugates for increased viral replication efficiency and potentiated cancer chemoimmunotherapy.

Journal: Biomaterials

Published: March 11, 2026

Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.

Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.

Journal: Journal of nanobiotechnology

Published: February 06, 2026

Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 13, 2026

Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy.

Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy.

Journal: ACS nano

Published: December 11, 2025

Correction to "Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy".

Correction to "Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy".

Journal: Nano letters

Published: August 04, 2025

In Situ Sustained Delivery of Tumor Cell-Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy.

In Situ Sustained Delivery of Tumor Cell-Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy.

Journal: Journal of extracellular vesicles

Published: June 04, 2025

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Journal: Nature communications

Published: April 21, 2025

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy.

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy.

Journal: Cell

Published: April 08, 2025

An inhalable microbe-oncolytic virus consortium for lung cancer treatment.

An inhalable microbe-oncolytic virus consortium for lung cancer treatment.

Journal: Cell reports. Medicine

Published: January 24, 2025

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 31, 2024

Microneedle-based nanodrugs for tumor immunotherapy.

Microneedle-based nanodrugs for tumor immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: October 13, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026